ImmunoGen
Inc. (Nasdaq: IMGN) impressed with sharply higher second quarter revenue
and earnings of 16 cents per share compared with 4 cents per share a
year earlier that surpassed analyst expectations by a wide margin. Shares of the biotechnology company climbed $1.43 to close at $7.63.
ImmunoGen impresses
January 30, 2015 at 18:09 PM EST